metformin has been researched along with trametinib in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Esteve-Puig, R; Kwong, A; Murphy, R; Ortiz-Urda, S; Posch, C; Rappersberger, K; Sanlorenzo, M; Tsumura, A; Vujic, I; Yen, AJ | 1 |
Allo, G; Carey, MS; Chhina, J; Dai, J; Giri, S; Llaurado, M; Mert, I; Munkarah, AR; Rattan, R; Seward, S | 1 |
Lee, Y; Park, D | 1 |
Déri, J; Dirner, A; Dóczi, R; Horváth, K; Kajáry, K; Lakatos, D; Lengyel, CG; Perjési, A; Peták, I; Remenár, É; Schwáb, R; Sipos, A; Tihanyi, D; Vályi-Nagy, I; Várkondi, E; Vodicska, B | 1 |
5 other study(ies) available for metformin and trametinib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; GTP Phosphohydrolases; Humans; Immunoblotting; MAP Kinase Signaling System; Membrane Proteins; Metformin; Mice, Nude; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Topics: AMP-Activated Protein Kinases; Antimetabolites; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; ras Proteins; Signal Transduction | 2017 |
Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Melanoma; Metformin; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Signal Transduction; Skin Neoplasms | 2021 |
Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Drug Combinations; Humans; Male; MAP Kinase Kinase 1; Metformin; Mutation; Neoplasm Recurrence, Local; Pyridones; Pyrimidinones; Skin Neoplasms; Time Factors; Treatment Outcome | 2022 |